Response Variability to Drug Testing in Two Models of Chemically Induced Colitis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076424 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Roger Suau und 13 weiteren Autor:innen. Beteiligte Einrichtung: IBD Research Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain. Hauptthemen laut MEDLINE: Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Spherium Biomed, Spherium Biotech (Barcelona, Spain).
Abstract (Originalsprache)
The lack of knowledge regarding the pathogenesis of IBD is a challenge for the development of more effective and safer therapies. Although in vivo preclinical approaches are critical for drug testing, none of the existing models accurately reproduce human IBD. Factors that influence the intra-individual response to drugs have barely been described. With this in mind, our aim was to compare the anti-inflammatory efficacy of a new molecule (MTADV) to that of corticosteroids in TNBS and DSS-induced colitis mice of both sexes in order to clarify further the response mechanism involved and the variability between sexes. The drugs were administered preventively and therapeutically, and real-time bioluminescence was performed for the in vivo time-course colitis monitoring. Morphometric data were also collected, and colonic cytokines and acute plasma phase proteins were analyzed by qRT-PCR and ELISA, respectively—bioluminescence images correlated with inflammatory markers. In the TNBS model, dexamethasone worked better in females, while MTADV improved inflammation in males. In DSS-colitis, both therapies worked similarly. Based on the molecular profiles, interaction networks were constructed to pinpoint the drivers of therapeutic response that were highly dependent on the sex. In conclusion, our results suggest the importance of considering sex in IBD preclinical drug screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IBD Research Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.
- Laboratory of Genetic Metabolic Diseases, Faculty of Biosciences, National University of San Marcos, Lima 15088, Peru.
- Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
- Hepatology Unit IGTP, 08916 Badalona, Spain.
- Department of Physiology, Faculty of Veterinary, Autonomous University of Barcelona, 08193 Bellaterra, Spain.
ORCID-Profile: Roger Suau, Eva Jou-Ollé, Míriam Mañosa, Eugeni Domènech
Förderung
- Instituto de Salud Carlos III
- Spherium Biomed
- Spherium Biotech (Barcelona, Spain)
- CIBEREHD (Madrid, Spain)
Zitieren
APA
Suau, R., Garcia, A., Bernal, C., Llaves, M., Schiering, K., Jou-Ollé, E., Pertegaz, A., Garcia-Jaraquemada, A., Bartolí, R., Lorén, V., Vergara, P., Mañosa, M., Domènech, E., & Manyé, J. (2023). Response Variability to Drug Testing in Two Models of Chemically Induced Colitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076424
Vancouver
Suau R, Garcia A, Bernal C, Llaves M, Schiering K, Jou-Ollé E, et al. Response Variability to Drug Testing in Two Models of Chemically Induced Colitis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076424
BibTeX
@article{Suau2023,
author = {Suau, Roger and Garcia, Anna and Bernal, Carla and Llaves, Mariona and Schiering, Katharina and Jou-Ollé, Eva and Pertegaz, Alex and Garcia-Jaraquemada, Arce and Bartolí, Ramon and Lorén, Violeta and Vergara, Patri and Mañosa, Míriam and Domènech, Eugeni and Manyé, Josep},
title = {Response Variability to Drug Testing in Two Models of Chemically Induced Colitis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076424}
}
EUVIMED